BlogsDataInsights Why you need key opinion leaders (KOLs) in your medical device marketing strategy In this blog post, we’ll discuss the importance of KOLs and thought leaders in marketing…Prashant SharmaDecember 20, 2022
DataFeaturedInsightsR&D TechnologyWhitepapers Accelerating discovery and creating value Pharmas and biotechs are united by a common goal: discovery. Whether seeking new treatments, improved…Ben.frew@excelra.comOctober 20, 2022
DataWhitepapers Training machine learning algorithms on different data scales Poor drug solubility is one of the main obstacles in drug discovery and development and…Ben.frew@excelra.comOctober 20, 2022
Clinical Data ServicesDataOur ThinkingWhitepapers Optimizing preclinical toxicology data analysis with comprehensive, digitized reports To understand a drug's effect on the body, investigations take place to understand the pharmacokinetic…Ben.frew@excelra.comOctober 18, 2022
BlogsData Ontologies and the FAIR data principles The FAIR principles: to make data “Findable”,” Accessible”, “Interoperable”, and “Re-usable”, stem from the notion…Ben.frew@excelra.comJuly 1, 2022
BlogsDataInsights Using legacy and current data to accelerate drug development As the pharmaceutical industry faces rising research and development costs (R&D) costs per drug brought…Ben.frew@excelra.comApril 16, 2022
BlogsDataR&D Technology Semantic metadata catalog for metadata management Traditional techniques of Data Cataloging at a data storage level creates dispersed data silos across…Ben.frew@excelra.comApril 16, 2022
BlogsData Bringing data to life with KOLs Who are KOLs? KOLs are key opinion leaders. They are experts in their scientific or…Prashant SharmaApril 16, 2022
BlogsData The impact of key opinion leaders (KOLs) on the delivery of emerging novel treatments to lung cancer patients Lung cancer is one of the most common causes of death worldwide, accounting for 1.8m…Prashant SharmaApril 16, 2022
BlogsData Repurposed drugs for COVID-19 Drug repurposing or repositioning is a promising approach for identifying new indications for approved or…Ben.frew@excelra.comApril 16, 2022